#BEGIN_DRUGCARD DB00259

# AHFS_Codes:
92:02.00*

# ATC_Codes:
D06BA05
J01EB06

# Absorption:
Sulfonamides are absorbed through the vaginal mucosa. There are no pharmacokinetic data available describing how much of an intravaginal dose reaches the systemic circulation.

# Biotransformation:
Not Available

# Brand_Mixtures:
After Calf Bolus (Sulfanilamide + Sulfathiazole + Urea)
Pinkamin (Methyl Salicylate + O-Phenylphenol + Sodium Thiosulfate + Sulfanilamide + Sulfur + Zinc Oxide)
Proud Flesh Dust (Boric Acid + Copper Sulfate + Sulfanilamide + Sulfathiazole + Tannic Acid)
Scour Bolus Plus (Calcium Carbonate + Magnesium Oxide + Menadione (Menadione Sodium Bisulfite) + Neomycin (Neomycin Sulfate) + Potassium Acetate + Sodium Acetate + Sodium Chloride + Streptomycin (Streptomycin Sulfate) + Sulfamerazine + Sulfamethazine + Sulfanilamide + Sulfathiazole + Vitamin a + Vitamin D)
Sulectim Plus Scour Boluses (Calcium Carbonate + Magnesium Oxide + Menadione Sodium Bisulfite + Neomycin (Neomycin Sulfate) + Potassium Acetate + Sodium Acetate + Sodium Chloride + Streptomycin (Streptomycin Sulfate) + Sulfamerazine + Sulfamethazine + Sulfanilamide + Sulfathiazole Sodium + Vitamin a + Vitamin D)
Sulfa Urea Crm (Sulfanilamide + Sulfathiazole + Urea)
Sulfa-Urea-Bolus (Sulfanilamide + Sulfathiazole + Urea)
Triple Sulfa Bolus (Sulfamethazine + Sulfanilamide + Sulfathiazole)
Triple Sulfa Bolus 240gr (Sulfamethazine + Sulfanilamide + Sulfathiazole)

# Brand_Names:
AVC
Albexan
Albosal
Ambeside
Antistrept
Astreptine
Astrocid
Bacteramid
Bactesid
Collomide
Colsulanyde
Copticide
Deseptyl
Desseptyl
Dipron
Ergaseptine
Erysipan
Estreptocida
Exoseptoplix
Fourneau 1162
Gerison
Gombardol
HSDB 223
Infepan
Lusil
Lysococcine
Neococcyl
Orgaseptine
Prontalbin
Prontosil Album
Prontosil I
Prontosil White
Prontylin
Pronzin Album
Proseptal
Proseptine
Proseptol
Pysococcine
Rubiazol A
Sanamid
Septamide Album
Septanilam
Septinal
Septolix
Septoplex
Septoplix
Stopton Album
Stramid
Strepamide
Strepsan
Streptagol
Streptamid
Streptamin
Streptasol
Streptocid
Streptocid Album
Streptocide
Streptocide White
Streptocidum
Streptoclase
Streptocom
Streptol
Strepton
Streptopan
Streptosil
Streptozol
Streptozone
Streptrocide
Sulfamidyl
Sulfamine
Sulfana
Sulfanalone
Sulfanidyl
Sulfanil
Sulfanilamide Vaginal Cream
Sulfocidin
Sulfocidine
Sulfonamide
Sulfonamide P
Sulphanilamide Extra Pure
Sulphanilamide Gr
Therapol
Tolder
White Streptocide

# CAS_Registry_Number:
63-74-1

# ChEBI_ID:
9333

# Chemical_Formula:
C6H8N2O2S

# Chemical_IUPAC_Name:
4-aminobenzene-1-sulfonamide

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2236620

# Description:
Sulfanilamide is a molecule containing the sulfonamide functional group attached to an aniline. [Wikipedia]

# Dosage_Forms:
Liquid	Oral

# Drug_Category:
Anti-Bacterial Agents
Homeopathic Agents
Sulfonamides

# Drug_Interactions:
Not Available

# Drug_Reference:
16997145	Nzila A: Inhibitors of de novo folate enzymes in Plasmodium falciparum. Drug Discov Today. 2006 Oct;11(19-20):939-44. Epub 2006 Sep 7.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-0.62

# Experimental_Logs:
-1.36

# Experimental_Water_Solubility:
7500 mg/L (at 25 °C)

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Sulfanilamide

# HET_ID:
SAN

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C6H8N2O2S/c7-5-1-3-6(4-2-5)11(8,9)10/h1-4H,7H2,(H2,8,9,10)

# InChI_Key:
InChIKey=FDDDEECHVMSUSB-UHFFFAOYSA-N

# Indication:
For the treatment of vulvovaginitis caused by <i>Candida albicans</i>.

# KEGG_Compound_ID:
C07458

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
259

# Mechanism_Of_Action:
Sulfanilamide is a competitive inhibitor of bacterial enzyme dihydropteroate synthetase. This enzyme normally uses para-aminobenzoic acid (PABA) for synthesizing the necessary folic acid. The inhibited reaction is normally necessary in these organisms for the synthesis of folic acid. Without it, bacteria cannot replicate.

# Melting_Point:
165.5 °C

# Molecular_Weight_Avg:
172.205

# Molecular_Weight_Mono:
172.0306482

# Organisms_Affected:
Candida albicans and other yeasts

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA451545

# Pharmacology:
Sulfanilamide is a sulfonamide antibiotic. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of <i>p</i>-aminobenzoic acid in the folic acid metabolism cycle. Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally. However, parenteral administration is difficult, since the soluble sulfonamide salts are highly alkaline and irritating to the tissues. The sulfonamides are widely distributed throughout all tissues. High levels are achieved in pleural, peritoneal, synovial, and ocular fluids. Although these drugs are no longer used to treat meningitis, CSF levels are high in meningeal infections. Their antibacterial action is inhibited by pus.

# Predicted_LogP_Hydrophobicity:
-0.16

# Predicted_LogS:
-1.2

# Predicted_Water_Solubility:
1.04e+01 g/l

# Primary_Accession_No:
DB00259

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
5333

# PubChem_Substance_ID:
46508306

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
APRD00438

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NC1=CC=C(C=C1)S(N)(=O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
P-Aminobenzenesulfamide
P-Aminobenzenesulfonamide
P-Aminobenzenesulfonylamide
P-Aminobenzensulfonamide
P-Aminophenylsulfonamide
P-Anilinesulfonamide
P-Sulfamidoaniline
P-Sulfamoylaniline
PABS
Sulfanilimidic Acid
Sulfonylamide
Sulphanilamide
Sulphonamide

# Synthesis_Reference:
Not Available

# Toxicity:
Oral, mouse LD<sub>50</sub> = 3700 mg/kg; Intravenous, mouse LD<sub>50</sub> = 621 mg/kg; Oral, rabbit LD<sub>50</sub> = 1300 mg/kg. Side effects include itching, burning, skin rash, redness, swelling, or other sign of irritation not present before use of this medicine and long-term use of sulfonamides may cause cancer of the thyroid gland.

# Update_Date:
2013-02-08 16:19:12 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Sulfanilamide

# pKa_Isoelectric_Point:
10.6 (at 20 °C)

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP2D6

# Phase_1_Metabolizing_Enzyme_1_ID:
4119

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 2D6

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 2D6
MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVDFQNTPYCFDQ
LRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVF
LARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDK
AVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVLLHIPALAGKV
LRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVA
DLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVI
HEVQRFGDIVPLGVTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHF
LDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGV
FAFLVSPSPYELCAVPR

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P10635

# Phase_1_Metabolizing_Enzyme_2_Gene_Name:
CYP3A4

# Phase_1_Metabolizing_Enzyme_2_ID:
4512

# Phase_1_Metabolizing_Enzyme_2_Name:
Cytochrome P450 3A4

# Phase_1_Metabolizing_Enzyme_2_Protein_Sequence:
>Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA

# Phase_1_Metabolizing_Enzyme_2_SwissProt_ID:
P08684

# Phase_1_Metabolizing_Enzyme_3_Gene_Name:
CYP2C9

# Phase_1_Metabolizing_Enzyme_3_ID:
4757

# Phase_1_Metabolizing_Enzyme_3_Name:
Cytochrome P450 2C9

# Phase_1_Metabolizing_Enzyme_3_Protein_Sequence:
>Cytochrome P450 2C9
MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDISKSLTNLSKV
YGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKKW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFHKRFDYKDQQFLNLMEKLNENIKILSSPWIQICNNFSPIIDYFPGTHNKLLKNVAFM
KSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYID
LLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDPHHFLDEGGNFK
KSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASVP
PFYQLCFIPV

# Phase_1_Metabolizing_Enzyme_3_SwissProt_ID:
P11712

# Phase_1_Metabolizing_Enzyme_4_Gene_Name:
CYP2E1

# Phase_1_Metabolizing_Enzyme_4_ID:
6013

# Phase_1_Metabolizing_Enzyme_4_Name:
Cytochrome P450 2E1

# Phase_1_Metabolizing_Enzyme_4_Protein_Sequence:
>Cytochrome P450 2E1
MSALGVTVALLVWAAFLLLVSMWRQVHSSWNLPPGPFPLPIIGNLFQLELKNIPKSFTRL
AQRFGPVFTLYVGSQRMVVMHGYKAVKEALLDYKDEFSGRGDLPAFHAHRDRGIIFNNGP
TWKDIRRFSLTTLRNYGMGKQGNESRIQREAHFLLEALRKTQGQPFDPTFLIGCAPCNVI
ADILFRKHFDYNDEKFLRLMYLFNENFHLLSTPWLQLYNNFPSFLHYLPGSHRKVIKNVA
EVKEYVSERVKEHHQSLDPNCPRDLTDCLLVEMEKEKHSAERLYTMDGITVTVADLFFAG
TETTSTTLRYGLLILMKYPEIEEKLHEEIDRVIGPSRIPAIKDRQEMPYMDAVVHEIQRF
ITLVPSNLPHEATRDTIFRGYLIPKGTVVVPTLDSVLYDNQEFPDPEKFKPEHFLNENGK
FKYSDYFKPFSTGKRVCAGEGLARMELFLLLCAILQHFNLKPLVDPKDIDLSPIHIGFGC
IPPRYKLCVIPRS

# Phase_1_Metabolizing_Enzyme_4_SwissProt_ID:
P05181

# Phase_1_Metabolizing_Enzyme_5_Gene_Name:
CYP2C19

# Phase_1_Metabolizing_Enzyme_5_ID:
6016

# Phase_1_Metabolizing_Enzyme_5_Name:
Cytochrome P450 2C19

# Phase_1_Metabolizing_Enzyme_5_Protein_Sequence:
>Cytochrome P450 2C19
MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDVSKSLTNLSKI
YGPVFTLYFGLERMVVLHGYEVVKEALIDLGEEFSGRGHFPLAERANRGFGIVFSNGKRW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFQKRFDYKDQQFLNLMEKLNENIRIVSTPWIQICNNFPTIIDYFPGTHNKLLKNLAFM
ESDILEKVKEHQESMDINNPRDFIDCFLIKMEKEKQNQQSEFTIENLVITAADLLGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVVGRNRSPCMQDRGHMPYTDAVVHEVQRYID
LIPTSLPHAVTCDVKFRNYLIPKGTTILTSLTSVLHDNKEFPNPEMFDPRHFLDEGGNFK
KSNYFMPFSAGKRICVGEGLARMELFLFLTFILQNFNLKSLIDPKDLDTTPVVNGFASVP
PFYQLCFIPV

# Phase_1_Metabolizing_Enzyme_5_SwissProt_ID:
P33261

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
16487326	Djapa LY, Zelikson R, Delahodde A, Bolotin-Fukuhara M, Mazabraud A: Plasmodium vivax dihydrofolate reductase as a target of sulpha drugs. FEMS Microbiol Lett. 2006 Mar;256(1):105-11.
16997145	Nzila A: Inhibitors of de novo folate enzymes in Plasmodium falciparum. Drug Discov Today. 2006 Oct;11(19-20):939-44. Epub 2006 Sep 7.
9127492	Prabhu V, Lui H, King J: Arabidopsis dihydropteroate synthase: general properties and inhibition by reaction product and sulfonamides. Phytochemistry. 1997 May;45(1):23-7.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X68776

# Drug_Target_1_GenBank_ID_Protein:
41273

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
folP

# Drug_Target_1_Gene_Sequence:
>849 bp
ATGAAACTTTTTGCCCAGGGTACTTCACTGGACCTTAGCCATCCTCACGTAATGGGGATC
CTCAACGTCACGCCTGATTCCTTTTCGGATGGTGGCACGCATAACTCGCTGATAGATGCG
GTGAAACATGCGAATCTGATGATCAACGCTGGCGCGACGATCATTGACGTTGGTGGCGAG
TCCACGCGCCCAGGGGCGGCGGAAGTTAGCGTTGAAGAAGAGTTGCAACGTGTTATTCCT
GTGGTTGAGGCAATTGCTCAACGCTTCGAAGTCTGGATCTCAGTCGATACATCCAAACCA
GAAGTCATCCGTGAGTCAGCGAAAGTTGGCGCTCACATTATTAATGATATCCGCTCCCTT
TCCGAACCTGGCGCTCTGGAGGCGGCTGCAGAAACCGGTTTACCGGTTTGTCTGATGCAT
ATGCAGGGAAATCCAAAAACCATGCAGGAAGCTCCGAAGTATGACGATGTCTTTGCAGAA
GTGAATCGCTACTTTATTGAGCAAATAGCACGTTGCGAGCAGGCGGGTATCGCAAAAGAG
AAATTGTTGCTCGACCCCGGATTCGGTTTCGGTAAAAATCTCTCCCATAACTATTCATTA
CTGGCGCGCCTGGCTGAATTTCACCATTTCAACCTGCCGCTGTTGGTGGGTATGTCACGA
AAATCGATGATTGGGCAGCTGCTGAACGTGGGGCCGTCCGAGCGCCTGAGCGGTAGTCTG
GCCTGTGCGGTCATTGCCGCAATGCAAGGCGCGCACATCATTCGTGTTCATGACGTCAAA
GAAACCGTAGAAGCGATGCGGGTGGTGGAAGCCACTCTGTCTGCAAAGGAAAACAAACGC
TATGAGTAA

# Drug_Target_1_General_Function:
Coenzyme transport and metabolism

# Drug_Target_1_General_References:
1522070	Dallas WS, Gowen JE, Ray PH, Cox MJ, Dev IK: Cloning, sequencing, and enhanced expression of the dihydropteroate synthase gene of Escherichia coli MC4100. J Bacteriol. 1992 Sep;174(18):5961-70.
1657875	Talarico TL, Dev IK, Dallas WS, Ferone R, Ray PH: Purification and partial characterization of 7,8-dihydro-6-hydroxymethylpterin-pyrophosphokinase and 7,8-dihydropteroate synthase from Escherichia coli MC4100. J Bacteriol. 1991 Nov;173(21):7029-32.
8304179	Swedberg G, Fermer C, Skold O: Point mutations in the dihydropteroate synthase gene causing sulfonamide resistance. Adv Exp Med Biol. 1993;338:555-8.
9187658	Achari A, Somers DO, Champness JN, Bryant PK, Rosemond J, Stammers DK: Crystal structure of the anti-bacterial sulfonamide drug target dihydropteroate synthase. Nat Struct Biol. 1997 Jun;4(6):490-7.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
891

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
30616

# Drug_Target_1_Name:
Dihydropteroate synthase

# Drug_Target_1_Number_of_Residues:
282

# Drug_Target_1_PDB_ID:
1AJZ

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00809	Pterin_bind

# Drug_Target_1_Protein_Sequence:
>Dihydropteroate synthase
MKLFAQGTSLDLSHPHVMGILNVTPDSFSDGGTHNSLIDAVKHANLMINAGATIIDVGGE
STRPGAAEVSVEEELQRVIPVVEAIAQRFEVWISVDTSKPEVIRESAKVGAHIINDIRSL
SEPGALEAAAETGLPVCLMHMQGNPKTMQEAPKYDDVFAEVNRYFIEQIARCEQAGIAKE
KLLLDPGFGFGKNLSHNYSLLARLAEFHHFNLPLLVGMSRKSMIGQLLNVGPSERLSGSL
ACAVIAAMQGAHIIRVHDVKETVEAMRVVEATLSAKENKRYE

# Drug_Target_1_Reaction:
(2-amino-4-hydroxy-7,8-dihydropteridin-6-yl)methyl diphosphate + 4-aminobenzoate = diphosphate + 7,8-dihydropteroate

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
DHPS catalyzes the formation of the immediate precursor of folic acid. It is implicated in resistance to sulfonamide

# Drug_Target_1_SwissProt_ID:
P0AC13

# Drug_Target_1_SwissProt_Name:
DHPS_ECOLI

# Drug_Target_1_Synonyms:
DHPS
Dihydropteroate pyrophosphorylase
EC 2.5.1.15

# Drug_Target_1_Theoretical_pI:
5.95

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB00259
